본문 바로가기
KERD
논문KCI 등재

비호지킨림프종 환자의 발열성 호중구감소증에 대한 페그필그라스팀의 예방효과

Prophylactic Effect of Pegfilgrastim on Febrile Neutropenia in Patients with Non-Hodgikin’s Lymphoma

방준석|조주희
한국임상약학회 (Korean College Of Clinical Pharmacy)|2015.06|한국임상약학회지 (Korean Journal of Clinical Pharmacy)|제25권 제2호|pp. 80-93

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

risk factorpegfilgrastimfebrile neutropenianon-hodgikin's lymphomaR-CHOP regimengranulocyte colony stimulating factor
주제분류약학

초록

Objective: Pegfilgrastim is recently introduced that is long acting G-CSF for prophylaxis of febrile neutropenia. Treatment of non- Hodgikin's lymphoma (NHL) with R-CHOP is classified with relative high risk of febrile neutropenia. The study evaluated the prophylactic effect of pegfilgrastim to reduce the incidence of febrile neutropenia associated with R-CHOP of patient in NHL. And the risk factors associated with the incidence of FN and related events were evaluated. Methods: This retrospective study reviews the Electronic Medical Record of 68 NHL patients who received R-CHOP chemotherapy in single center between September 2013 and August 2014. These patients were classified who receive prophylaxis pegfilgrastim or no prophylaxis. Results: Sixty eight patients received R-CHOP with NHL. In 144 cycles of patients receiving pegfilgrastim, compared with no prophylaxis 178 cycles, had a lower incidence of febrile neutropenia (5.5% vs. 23.6%, p = 0.001), grade 3 or grade 4 neutropenia (14.4% vs. 89.8%, p < 0.001) and neutropenia related events (p < 0.05). The risk of febrile neutropenia after prophylaxis was significantly associated with age ≥ 65 (OR: 5.87, 95% CI 1.07-32.27, p = 0.042), IPI ≥ 3 (OR: 7.2, 95% CI 1.31-39.6, p = 0.023), S.alb < 3.5 g/dL (OR: 31.01, 95% CI 6.32-152.17, p < 0.0001). In multiple logistic regression analysis, lower baseline serum albumin (OR: 21.1, 95% CI 3.8-116.98, p = 0.001) was significantly associated with occurrence of febrile neutropenia. Conclusion: The study recommends prophylactic pegfilgrastim through risk assessment of febrile neutropenia in patients with non-Hodgikin's lymphoma receiving R-CHOP.

Abstract

Objective: Pegfilgrastim is recently introduced that is long acting G-CSF for prophylaxis of febrile neutropenia. Treatment of non- Hodgikin's lymphoma (NHL) with R-CHOP is classified with relative high risk of febrile neutropenia. The study evaluated the prophylactic effect of pegfilgrastim to reduce the incidence of febrile neutropenia associated with R-CHOP of patient in NHL. And the risk factors associated with the incidence of FN and related events were evaluated. Methods: This retrospective study reviews the Electronic Medical Record of 68 NHL patients who received R-CHOP chemotherapy in single center between September 2013 and August 2014. These patients were classified who receive prophylaxis pegfilgrastim or no prophylaxis. Results: Sixty eight patients received R-CHOP with NHL. In 144 cycles of patients receiving pegfilgrastim, compared with no prophylaxis 178 cycles, had a lower incidence of febrile neutropenia (5.5% vs. 23.6%, p = 0.001), grade 3 or grade 4 neutropenia (14.4% vs. 89.8%, p < 0.001) and neutropenia related events (p < 0.05). The risk of febrile neutropenia after prophylaxis was significantly associated with age ≥ 65 (OR: 5.87, 95% CI 1.07-32.27, p = 0.042), IPI ≥ 3 (OR: 7.2, 95% CI 1.31-39.6, p = 0.023), S.alb < 3.5 g/dL (OR: 31.01, 95% CI 6.32-152.17, p < 0.0001). In multiple logistic regression analysis, lower baseline serum albumin (OR: 21.1, 95% CI 3.8-116.98, p = 0.001) was significantly associated with occurrence of febrile neutropenia. Conclusion: The study recommends prophylactic pegfilgrastim through risk assessment of febrile neutropenia in patients with non-Hodgikin's lymphoma receiving R-CHOP.

참고문헌 (56)

  1. Lyman GH., "Epidemiology of febrile neutropenia", Support Cancer Ther, 1(1), pp.23~35 (2003)
  2. Kuderer NM., "Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients", Cancer, 106(10), pp.2258~2266 (2006)
  3. Bhana N, "Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia : evidence based review", Curr Opin Oncol, 19(4), pp.328~335 (2007)
  4. 이동건, "Evidence-Based Guidelines for Empirical Therapy of Neutropenic Fever in Korea", The Korean Journal of Internal Medicine, 26(2), pp.220~252 (2011), 대한내과학회
  5. Lyman GH., "Filgrastim in patients with neutropenia: potential effects on quality of life", Drugs, 62(Suppl 1), pp.65~78 (2002)
  6. "National cancer center. Annual Report 2011"[URL]
  7. Harris NL., "A revised European-American classification of lymphoid neoplasms : a proposal from the International Lymphoma Study Group", Blood, 84(5), pp.1361~1392 (1994)
  8. Boyiadzis M., "Williams Hematology. 8 ed" (2010)
  9. Coiffier B., "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma", N Engl J Med, 346(4), pp.235~242 (2002)
  10. Pfreundschuh M., "Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas : a randomised controlled trial(RICOVER-60)", Lancet Oncol, 9(2), pp.105~116 (2008)
  11. Delarue R., "Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma(the LNH03-6B study) : a randomised phase 3 trial", Lancet Oncol, 14(6), pp.525~533 (2013)
  12. Lee S., "Primary prophylaxis with granulocyte colony-stimulating factor(GCSF)reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma(NHL)receiving CHOP chemotherapy treatment without adversely affecting their quality of life : cost-benefit and quality of life analysis", Support Care Cancer, 21(3), pp.841~846 (2013)
  13. Cooper KL., "Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy : systematic review and meta-analysis", BMC Cancer, 11, pp.404~ (2011)
  14. Vogel CL., "First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer : a multicenter, double-blind, placebo-controlled phase III study", J Clin Oncol, 23(6), pp.1178~1184 (2005)
  15. Kuderer NM., "Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy : a systematic review", J Clin Oncol, 25(21), pp.3158~3167 (2007)
  16. Green MD., "A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy", Ann Oncol, 14(1), pp.29~35 (2003)
  17. Tan H., "Comparative effectiveness of colonystimulating factors for febrile neutropenia : a retrospective study", Curr Med Res Opin, 27(1), pp.79~86 (2011)
  18. Holmes FA., "Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III", IV breast cancer, 2002, pp.20(3), 727~731
  19. Naeim A., "Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis : a retrospective United States claims analysis of granulocyte colony-stimulating factors(G-CSF)", BMC Cancer, 13, pp.11~ (2013)
  20. Weycker D., "Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis : a retrospective cohort study", Clin Ther, 31(5), pp.1069~1081 (2009)
  21. Product Information., "NEULASTA(R) subcutaneous injection, pegfilgrastim subcutaneous injection" (2008), Amgen Manufacturing Limited
  22. "Clinical practice guidelines in oncology. Myeloid Growth Factors Version 2" (2014)[URL]
  23. Smith TJ., "2006 update of recommendations for the use of white blood cell growth factors : an evidencebased clinical practice guideline", J Clin Oncol, 24(19), pp.3187~3205 (2006)
  24. Lyman GH, "Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy : a review of the evidence", J Natl Compr Canc Netw, 3(4), pp.557~571 (2005)
  25. Aapro MS., "2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours", Eur J Cancer, 47(1), pp.8~32 (2011)
  26. "Anticancer medications and therapies"[URL]
  27. "Details about the applicable standards and methods of reimbursement (Notice of HIRA, No. 2013-209)"[URL]
  28. Langeberg WJ., "Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma", Support Care Cancer, 22(8), pp.2167~2175 (2014)
  29. Flores IQ., "Managing neutropenia in older patients with cancer receiving chemotherapy in a community setting", Clin J Oncol Nurs, 14(1), pp.81~86 (2010)
  30. Pfeil AM., "Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review", Support Care Cancer (2014)[DOI]
  31. Svetitsky S., "Comparative efficacy and safety of vancomycin versus teicoplanin : systematic review and meta-analysis", Antimicrob Agents Chemother, 53(10), pp.4069~4079 (2009)
  32. Robenshtok E., "Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation : systematic review and meta-analysis", J Clin Oncol, 25(34), pp.5471~5489 (2007)
  33. Perrier L., "Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma : an economic evaluation of the PALM Trial", Appl Health Econ Health Policy, 11(2), pp.129~138 (2013)
  34. Lyman G., "Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States", Curr Med Res Opin, 25(2), pp.401~411 (2009)
  35. Lathia N., "Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients", J Natl Cancer Inst, 105(15), pp.1078~1085 (2013)
  36. Chirivella I., "Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients", Breast Cancer Res Treat, 114(3), pp.479~484 (2009)
  37. Lyman GH., "Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma", Cancer, 98(11), pp.2402~2409 (2003)
  38. Balducci L., "Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim", Oncologist, 12(12), pp.1416~1424 (2007)
  39. Ozer H., "Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use", Oncologist, 12(4), pp.484~494 (2007)
  40. Johnston E., "Randomized, dose-escalation study of SD", 01 compared with daily filgrastim in patients receiving chemotherapy, 2000, pp.18(13), 2522~2528
  41. Garcia-Carbonero R., "Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia : a multicenter randomized trial", J Natl Cancer Inst, 93(1), pp.31~38 (2001)
  42. Clark OA., "Colony-stimulating factors for chemotherapy-induced febrile neutropenia : a meta-analysis of randomized controlled trials", J Clin Oncol, 23(18), pp.4198~4214 (2005)
  43. Berghmans T., "Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis", Support Care Cancer, 10(3), pp.181~188 (2002)
  44. Koumakis G., "Optimal timing(Preemptive versus supportive)of granulocyte colony-stimulating factor administration following high-dose cyclophosphamide", Oncology, 56(1), pp.28~35 (1999)
  45. Chan A., "Comparison of daily filgrastim and pegfilgrastim to prevent febrile neutropenia in Asian lymphoma patients", Asia Pac J Clin Oncol, 7(1), pp.75~81 (2011)
  46. Holmes FA., "Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia : a multicenter dosefinding study in women with breast cancer", Ann Oncol, 13(6), pp.903~909 (2002)
  47. Vose JM., "Randomized, multicenter, openlabel study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma", J Clin Oncol, 21(3), pp.514~519 (2003)
  48. Pettengell R., "Pegfilgrastim primary prophylaxis in patients with non-Hodgkin lymphoma : results from an integrated analysis", Hematol Oncol, 29(4), pp.177~184 (2011)
  49. Salar A., "The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21 : findings from clinical practice", Leuk Res, 36(5), pp.548~553 (2012)
  50. Lyman GH., "Risk models for predicting chemotherapy-induced neutropenia", Oncologist, 10(6), pp.427~437 (2005)
  51. Wieringa A., "Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP : a population-based cohort study", Br J Haematol, 165(4), pp.489~496 (2014)
  52. Lyman GH., "Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy", Leuk Lymphoma, 44(12), pp.2069~2076 (2003)
  53. Pettengell R., "Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma : data from the INC-EU Prospective Observational European Neutropenia Study", Br J Haematol, 144(5), pp.677~685 (2009)
  54. Chao C., "History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis", Ann Oncol (2014)[DOI]
  55. Le AT., "White blood cell growth factor use in an outpatient oncology clinic: Lessons and opportunities learned", J Oncol Pharm Pract (2014)[DOI]
  56. Waters GE., "Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic", J Oncol Pract, 9(4), pp.203~206 (2013)

관련 논문AI추천

Risk factors for neutropenic fever in non- Hodgkin’s lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis김수정, 김유리, 김진석, Hwan-Jung Yun, Sung Yong Oh, Yeung-Chul Mun, Yong Park대한내과학회 · The Korean Journal of Internal Medicine2021 · 제36권 제5호항암치료를 받는 미만성거대비세포 림프종 환자에서 페그필그라스팀에 대한 효용성 평가김정미, 민명숙, 방준석, 이영미, 정희원한국임상약학회 · 한국임상약학회지2015 · 제25권 제3호Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study박용, 강혜진, 고영일, 곽재용, 권지현, 김민경, 김석진, 김세형, 김원석, 김효정, 도영록, 박병배, 서철원, 손병석, 신호진, 양덕환, 엄현석, 오성용, 원종호, 유쾌한, 윤덕현, 윤환중, 이경원, 이성윤, 이원식, 이준호, 이호섭, 정성현, 조재철, 최윤석, 현신영대한암학회 · Cancer Research and Treatment2022 · 제54권 제4호Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia during R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma김도영, 김상우, 남제현, 신호진, 이지현, 전별은, 정주섭, 조재철대한암학회 · Cancer Research and Treatment2022 · 제54권 제4호Incidence and Clinical Outcomes of Febrile Neutropenia in Adult Cancer Patients with Chemotherapy Using Korean Nationwide Health Insurance Database김달용, 육태미, 이수현, 홍수정연세대학교의과대학 · Yonsei Medical Journal2021 · 제62권 제6호FOLFIRINOX/mFOLFIRINOX 요법을 사용하는 췌장암 환자에서 Eflapegrastim과 Pegteograstim의 항암화학요법으로 인한 호중구감소증 예방 효과 비교고종희, 금민정, 김재송, 손은선, 유윤미, 이의선한국병원약사회 · 병원약사회지2024 · 제41권 제3호

이 간행물의 다른 논문 (7건)

영국의 약사교육체계와 국가면허 시험제도 연구: England 와 Wales지역을 중심으로김윤정pp. 61-67우리나라와 캐나다 약학대학 실무실습 교과과정 비교강민구pp. 68-73제2형 당뇨병 환자에서 Metformin/Dipeptidyl Peptidase-4 저해제 병용요법과 Metformin/Sulfonylurea 병용요법간의 효과에 대한 비교 연구박지혜, 김재연, 김주희, 곽혜선, 박선이pp. 74-79지역약국 약료서비스 제공의 장애요인: 약사 대상 설문조사최상은, 안형태, 김성옥, 주경미, 박혜경, 한은아, 손현순pp. 94-101지역약국 필수실무실습에 관한 프리셉터와 학생의 인식 비교이정연, 진혜경, 강지은, 박지영pp. 102-110
원문 보기